Awakening the immune system with radiation: Optimal dose and fractionation

Cancer Letters

Volumn 368, Issue 2, 2015, Pages 185-190

  Gandhi, Saumil J ^a   Minn, Andy J ^a,b   Vonderheide, Robert H ^a,b   Wherry, E John ^a,b   Hahn, Stephen M ^a   Maity, Amit ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Dose; Fractionation; Immunotherapy; Radiation

Indexed keywords

ANTINEOPLASTIC AGENT; CELL SURFACE RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; PROGRAMMED DEATH 1 ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIGEN PRESENTATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; HUMAN; IMMUNE RESPONSE; METASTATIC MELANOMA; MOLECULAR DYNAMICS; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIATION DOSE FRACTIONATION; RADIOIMMUNOTHERAPY; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR IMMUNITY; ANIMAL; IMMUNE SYSTEM; IMMUNOLOGY; NEOPLASMS; PROCEDURES; RADIATION RESPONSE;

ANIMALS; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; IMMUNE SYSTEM; NEOPLASMS; RADIOTHERAPY;

EID: 84941873674     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.03.024     Document Type: Review

References (35)

1. Formenti S.C., Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J. Natl. Cancer Inst 2013, 105:256-265.
2. Zeng J., Harris T.J., Lim M., Drake C.G., Tran P.T. Immune modulation and stereotactic radiation: improving local and abscopal responses. Biomed Res. Int 2013, 2013. 658126.
3. Tang C., Wang X., Soh H., Seyedin S., Cortez M.A., Krishnan S., et al. Combining radiation and immunotherapy: a new systemic therapy for solid tumors?. Cancer Immunol. Res 2014, 2:831-838.
4. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012, 12:252-264.
5. Burnette B., Fu Y.X., Weichselbaum R.R. The confluence of radiotherapy and immunotherapy. Front. Oncol 2012, 2:143.
6. Shiao S.L., Coussens L.M. The tumor-immune microenvironment and response to radiation therapy. J. Mammary Gland Biol. Neoplasia 2010, 15:411-421.
7. Owen-Schaub L.B. Fas function and tumor progression: use it and lose it. Cancer Cell 2002, 2:95-96.
8. Stone H.B., Peters L.J., Milas L. Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma. J. Natl. Cancer Inst 1979, 63:1229-1235.
9. Chakravarty P.K., Alfieri A., Thomas E.K., Beri V., Tanaka K.E., Vikram B., et al. Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer. Cancer Res 1999, 59:6028-6032.
10. Gaugler M.H., Squiban C., van der Meeren A., Bertho J.M., Vandamme M., Mouthon M.A. Late and persistent up-regulation of intercellular adhesion molecule-1 (ICAM-1) expression by ionizing radiation in human endothelial cells in vitro. Int. J. Radiat. Biol 1997, 72:201-209.
11. Chakraborty M., Abrams S.I., Camphausen K., Liu K., Scott T., Coleman C.N., et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J. Immunol 2003, 170:6338-6347.
12. Chakraborty M., Abrams S.I., Coleman C.N., Camphausen K., Schlom J., Hodge J.W. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res 2004, 64:4328-4337.
13. Reits E.A., Hodge J.W., Herberts C.A., Groothuis T.A., Chakraborty M., Wansley E.K., et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J. Exp. Med 2006, 203:1259-1271.
14. Garnett C.T., Palena C., Chakraborty M., Tsang K.Y., Schlom J., Hodge J.W. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004, 64:7985-7994.
15. Lugade A.A., Moran J.P., Gerber S.A., Rose R.C., Frelinger J.G., Lord E.M. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J. Immunol 2005, 174:7516-7523.
16. Lee Y., Auh S.L., Wang Y., Burnette B., Meng Y., Beckett M., et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 2009, 114:589-595.
17. Schaue D., Ratikan J.A., Iwamoto K.S., McBride W.H. Maximizing tumor immunity with fractionated radiation. Int. J. Radiat. Oncol. Biol. Phys 2012, 83:1306-1310.
18. Melero I., Hervas-Stubbs S., Glennie M., Pardoll D.M., Chen L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev. Cancer 2007, 7:95-106.
19. Hodi F.S., Day S.J.O., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med 2010, 363:711-723.
20. Demaria S., Kawashima N., Yang A.M., Devitt M.L., Babb J.S., Allison J.P., et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin. Cancer Res 2005, 11:728-734.
21. Dewan M.Z., Galloway A.E., Kawashima N., Dewyngaert J.K., Babb J.S., Formenti S.C., et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin. Cancer Res 2009, 15:5379-5388.
22. Blank C., Brown I., Peterson A.C., Spiotto M., Iwai Y., Honjo T., et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 2004, 64:1140-1145.
23. Hamid O., Robert C., Daud A., Hodi F.S., Hwu W.J., Kefford R., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med 2013, 369:134-144.
24. Wolchok J.D., Kluger H., Callahan M.K., Postow M.A., Rizvi N.A., Lesokhin A.M., et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med 2013, 369:122-133.
25. Verbrugge I., Hagekyriakou J., Sharp L.L., Galli M., West A., McLaughlin N.M., et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res 2012, 72:3163-3174.
26. Zeng J., See A.P., Phallen J., Jackson C.M., Belcaid Z., Ruzevick J., et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int. J. Radiat. Oncol. Biol. Phys 2013, 86:343-349.
27. Deng L., Liang H., Burnette B., Beckett M., Darga T., Weichselbaum R.R., et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest 2014, 124:687-695.
28. Twyman-Saint Victor C., Rech A.J., Maity A., Rengan R., Pauken K.E., Stelekati E., et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 2015, 10.1038/nature14292.
29. Postow M.A., Callahan M.K., Barker C.A., Yamada Y., Yuan J., Kitano S., et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med 2012, 366:925-931.
30. Hiniker S.M., Chen D.S., Reddy S., Chang D.T., Jones J.C., Mollick J.A., et al. A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl. Oncol 2012, 5:404-407.
31. Golden E.B., Demaria S., Schiff P.B., Chachoua A., Formenti S.C. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol. Res 2014, 1:365-372.
32. Slovin S.F., Higano C.S., Hamid O., Tejwani S., Harzstark A., Alumkal J.J., et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann. Oncol 2013, 24:1813-1821.
33. Seung S.K., Curti B.D., Crittenden M., Walker E., Coffey T., Siebert J.C., et al. Phase 1 study of stereotactic body radiotherapy and interleukin-2 - tumor and immunological responses. Sci. Transl. Med 2012, 4. 137ra174.
34. Lange J.R., Raubitschek A.A., Pockaj B.A., Spencer W.F., Lotze M.T., Topalian S.L., et al. A pilot study of the combination of interleukin-2-based immunotherapy and radiation therapy. J. Immunother 1992, 12:265-271.
35. Crittenden M., Kohrt H., Levy R., Jones J., Camphausen K., Dicker A., et al. Current clinical trials testing combinations of immunotherapy and radiation. Semin. Radiat. Oncol 2015, 25:54-64.